Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an upsized and oversubscribed $102 million financing. New and existing investors in the financing round include Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, and Spur Capital Partners.
UCSF is proud to support the research that came from Cory Nicholas, PhD, and was foundational to Neurona Therapeutics technology.